1932

Abstract

COVID-19 can cause acute kidney injury and may cause or exacerbate chronic kidney diseases, including glomerular diseases. SARS-CoV-2 infection of kidney cells has been reported, but it remains unclear if viral infection of kidney cells causes disease. The most important causes of kidney injury in patients with COVID-19 include impaired renal perfusion and immune dysregulation. Chronic kidney disease, especially kidney failure with kidney replacement therapy and kidney transplant, is associated with markedly increased COVID-19 mortality. Persons with severe kidney disease have been excluded from most clinical trials of COVID-19 therapies, so therapeutic approaches must be extrapolated from studies of patients without kidney disease. Some medications used to treat COVID-19 should be avoided or used at reduced dosages in patients with severe kidney disease and in kidney transplant recipients. Additional research is needed to determine the optimal strategies to prevent and treat COVID-19 in patients with kidney disease.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042420-104753
2023-01-27
2024-04-12
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-042420-104753.html?itemId=/content/journals/10.1146/annurev-med-042420-104753&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Wiersinga WJ, Rhodes A, Cheng AC et al. 2020. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324:782–93
    [Google Scholar]
  2. 2.
    Jackson CB, Farzan M, Chen B, Choe H 2022. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23:3–20
    [Google Scholar]
  3. 3.
    Diamond MS, Kanneganti TD. 2022. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 23:165–76
    [Google Scholar]
  4. 4.
    Khan S, Chen L, Yang CR et al. 2020. Does SARS-CoV-2 infect the kidney?. J. Am. Soc. Nephrol. 31:2746–48
    [Google Scholar]
  5. 5.
    Braun F, Lutgehetmann M, Pfefferle S et al. 2020. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 396:597–98
    [Google Scholar]
  6. 6.
    Puelles VG, Lutgehetmann M, Lindenmeyer MT et al. 2020. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383:590–92
    [Google Scholar]
  7. 7.
    Diao B, Wang C, Wang R et al. 2021. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun. 12:2506
    [Google Scholar]
  8. 8.
    Farkash EA, Wilson AM, Jentzen JM. 2020. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J. Am. Soc. Nephrol. 31:1683–87
    [Google Scholar]
  9. 9.
    Su H, Yang M, Wan C et al. 2020. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 98:219–27
    [Google Scholar]
  10. 10.
    Bullock HA, Goldsmith CS, Miller SE. 2021. Best practices for correctly identifying coronavirus by transmission electron microscopy. Kidney Int. 99:824–27
    [Google Scholar]
  11. 11.
    Roufosse C, Curtis E, Moran L et al. 2020. Electron microscopic investigations in COVID-19: not all crowns are coronas. Kidney Int. 98:505–6
    [Google Scholar]
  12. 12.
    Hassler L, Reyes F, Sparks M et al. 2021. Evidence for and against direct kidney infection by SARS-CoV-2 in patients with COVID-19. Clin. J. Am. Soc. Nephrol. 16:1755–65
    [Google Scholar]
  13. 13.
    Santoriello D, Khairallah P, Bomback AS et al. 2020. Postmortem kidney pathology findings in patients with COVID-19. J. Am. Soc. Nephrol. 31:2158–67
    [Google Scholar]
  14. 14.
    Jansen J, Reimer KC, Nagai JS et al. 2022. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell 29:217–31.e8
    [Google Scholar]
  15. 15.
    Birkelo BC, Parr SK, Perkins AM et al. 2021. Comparison of COVID-19 versus influenza on the incidence, features, and recovery from acute kidney injury in hospitalized United States Veterans. Kidney Int. 100:894–905
    [Google Scholar]
  16. 16.
    Chan L, Chaudhary K, Saha A et al. 2021. AKI in hospitalized patients with COVID-19. J. Am. Soc. Nephrol. 32:151–60
    [Google Scholar]
  17. 17.
    Alenezi FK, Almeshari MA, Mahida R et al. 2021. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and meta-analysis. Ren. Fail. 43:1621–33
    [Google Scholar]
  18. 18.
    Fu EL, Janse RJ, de Jong Y et al. 2020. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin. Kidney J. 13:550–63
    [Google Scholar]
  19. 19.
    Gupta S, Coca SG, Chan L et al. 2021. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 32:161–76
    [Google Scholar]
  20. 20.
    Palevsky PM. 2021. COVID-19 and AKI: Where do we stand?. J. Am. Soc. Nephrol. 32:1029–32
    [Google Scholar]
  21. 21.
    Legrand M, Bell S, Forni L et al. 2021. Pathophysiology of COVID-19-associated acute kidney injury. Nat. Rev. Nephrol. 17:751–64
    [Google Scholar]
  22. 22.
    Gupta S, Hayek SS, Wang W et al. 2020. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. 180:1436–47
    [Google Scholar]
  23. 23.
    Mocerino R, Kumar N. 2020. Acute abdominal pain in a COVID-19 patient. Kidney360 1:584–85
    [Google Scholar]
  24. 24.
    Chen W, Caplin N, El Shamy O et al. 2021. Use of peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City: a multicenter observational study. Kidney Int. 100:2–5
    [Google Scholar]
  25. 25.
    Nadim MK, Forni LG, Mehta RL et al. 2020. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 16:747–64
    [Google Scholar]
  26. 26.
    Ronco C, Reis T, Husain-Syed F. 2020. Management of acute kidney injury in patients with COVID-19. Lancet Respir. Med. 8:738–42
    [Google Scholar]
  27. 27.
    Procaccini FL, Alcázar Arroyo R, Albalate Ramón M et al. 2021. Acute kidney injury in 3182 patients admitted with COVID-19: a single center retrospective case–control study. Clin. Kidney J. 14:1557–69
    [Google Scholar]
  28. 28.
    Izzedine H, Jhaveri KD. 2021. Acute kidney injury in patients with COVID-19: an update on the pathophysiology. Nephrol. Dial. Transplant. 36:224–26
    [Google Scholar]
  29. 29.
    Sun S, Annadi RR, Chaudhri I et al. 2022. Short- and long-term recovery after moderate/severe AKI in patients with and without COVID-19. Kidney360 3:242–57
    [Google Scholar]
  30. 30.
    Bowe B, Xie Y, Xu E, Al-Aly Z. 2021. Kidney outcomes in long COVID. J. Am. Soc. Nephrol. 32:2851–62
    [Google Scholar]
  31. 31.
    Bowe B, Cai M, Xie Y et al. 2020. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin. J. Am. Soc. Nephrol. 16:14–25
    [Google Scholar]
  32. 32.
    Charytan DM, Parnia S, Khatri M et al. 2021. Decreasing incidence of acute kidney injury in patients with COVID-19 critical illness in New York City. Kidney Int. Rep. 6:916–27
    [Google Scholar]
  33. 33.
    Velez JCQ, Caza T, Larsen CP. 2020. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 16:565–67
    [Google Scholar]
  34. 34.
    Shetty AA, Tawhari I, Safar-Boueri L et al. 2021. COVID-19-associated glomerular disease. J. Am. Soc. Nephrol. 32:33–40
    [Google Scholar]
  35. 35.
    May RM, Cassol C, Hannoudi A et al. 2021. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 100:1303–15
    [Google Scholar]
  36. 36.
    Akilesh S, Nast CC, Yamashita M et al. 2021. Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria. Am. J. Kidney Dis. 77:82–93.e1
    [Google Scholar]
  37. 37.
    Kudose S, Batal I, Santoriello D et al. 2020. Kidney biopsy findings in patients with COVID-19. J. Am. Soc. Nephrol. 31:1959–68
    [Google Scholar]
  38. 38.
    Caza TN, Cassol CA, Messias N et al. 2021. Glomerular disease in temporal association with SARS-CoV-2 vaccination: a series of 29 cases. Kidney360 2:1770–80
    [Google Scholar]
  39. 39.
    Wu H, Larsen CP, Hernandez-Arroyo CF et al. 2020. AKI and collapsing glomerulopathy associated with COVID-19 and APOL 1 high-risk genotype. J. Am. Soc. Nephrol. 31:1688–95
    [Google Scholar]
  40. 40.
    Daneshpajouhnejad P, Kopp JB, Winkler CA, Rosenberg AZ. 2022. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18:307–20
    [Google Scholar]
  41. 41.
    Kudose S, Santoriello D, Bomback AS et al. 2021. Longitudinal outcomes of COVID-19-associated collapsing glomerulopathy and other podocytopathies. J. Am. Soc. Nephrol. 32:2958–69
    [Google Scholar]
  42. 42.
    Jefferis J, Kassianos AJ, Grivei A et al. 2022. SARS-CoV-2 vaccination-associated collapsing glomerulopathy in a kidney transplant recipient. Kidney Int. 101:635–36
    [Google Scholar]
  43. 43.
    Timmermans S, Busch MH, Abdul-Hamid MA et al. 2022. Primary podocytopathies after COVID-19 vaccination. Kidney Int. Rep. 7:892–94
    [Google Scholar]
  44. 44.
    Rivero J, Merino-Lopez M, Olmedo R et al. 2021. Association between postmortem kidney biopsy findings and acute kidney injury from patients with SARS-CoV-2 (COVID-19). Clin. J. Am. Soc Nephrol. 16:685–93
    [Google Scholar]
  45. 45.
    Klomjit N, Alexander MP, Fervenza FC et al. 2021. COVID-19 vaccination and glomerulonephritis. Kidney Int. Rep. 6:2969–78
    [Google Scholar]
  46. 46.
    Waldman M, Soler MJ, García-Carro C et al. 2022. COVID-19 in patients with glomerular disease: follow-up results from the IRoc-GN international registry. Kidney360 3:293–306
    [Google Scholar]
  47. 47.
    Wu HHL, Kalra PA, Chinnadurai R. 2021. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Vaccines 9:1252
    [Google Scholar]
  48. 48.
    Guo W, Tan PH, Baikunje S. 2022. Membranous nephropathy in a patient with COVID-19 infection. J. Nephrol. 35:351–55
    [Google Scholar]
  49. 49.
    Miao J, Fidler ME, Nasr SH et al. 2021. Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): a case report. Clin. Nephrol. Case Stud. 9:11–18
    [Google Scholar]
  50. 50.
    Beck LH Jr., Bonegio RG, Lambeau G et al. 2009. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361:11–21
    [Google Scholar]
  51. 51.
    Fenoglio R, Lalloni S, Marchisio M et al. 2022. New onset biopsy-proven nephropathies after COVID vaccination. Am. J. Nephrol. 53:325–30
    [Google Scholar]
  52. 52.
    Floege J, Amann K. 2016. Primary glomerulonephritides. Lancet 387:2036–48
    [Google Scholar]
  53. 53.
    Wyatt RJ, Julian BA. 2013. IgA nephropathy. N. Engl. J. Med. 368:2402–14
    [Google Scholar]
  54. 54.
    Almaani S, Meara A, Rovin BH. 2017. Update on lupus nephritis. Clin. J. Am. Soc. Nephrol. 12:825–35
    [Google Scholar]
  55. 55.
    Kim HJ, Jung M, Lim BJ, Han SH. 2022. New-onset class III lupus nephritis with multi-organ involvement after COVID-19 vaccination. Kidney Int. 101:826–28
    [Google Scholar]
  56. 56.
    Zavala-Miranda MF, González-Ibarra SG, Pérez-Arias AA et al. 2021. New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. Kidney Int. 100:1340–41
    [Google Scholar]
  57. 57.
    Tuschen K, Bräsen JH, Schmitz J et al. 2021. Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine. Kidney Int. 100:941–44
    [Google Scholar]
  58. 58.
    Ugarte-Gil MF, Alarcón GS, Izadi Z et al. 2022. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann. Rheum. Dis. 81:970–78
    [Google Scholar]
  59. 59.
    Izci Duran T, Turkmen E, Dilek M et al. 2021. ANCA-associated vasculitis after COVID-19. Rheumatol. Int. 41:1523–29
    [Google Scholar]
  60. 60.
    Fireizen Y, Shahriary C, Imperial ME et al. 2021. Pediatric P-ANCA vasculitis following COVID-19. Pediatr. Pulmonol. 56:3422–24
    [Google Scholar]
  61. 61.
    Uppal NN, Kello N, Shah HH et al. 2020. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int. Rep. 5:2079–83
    [Google Scholar]
  62. 62.
    Fillon A, Sautenet B, Barbet C et al. 2022. De novo and relapsing necrotizing vasculitis after COVID-19 vaccination. Clin. Kidney J. 15:560–63
    [Google Scholar]
  63. 63.
    Winkler A, Zitt E, Sprenger-Mähr H et al. 2021. SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report. BMC Nephrol. 22:75
    [Google Scholar]
  64. 64.
    Sebastian R, Arunachalam J, Rajendran M. 2021. Temporal clustering of antiglomerular basement membrane disease in COVID-19 pandemic: a case series. Int. J. Nephrol. Renovasc. Dis 14:393–98
    [Google Scholar]
  65. 65.
    Sacker A, Kung V, Andeen N. 2021. Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination. Kidney Int. 100:471–72
    [Google Scholar]
  66. 66.
    Nahhal S, Halawi A, Basma H Sr. et al. 2020. Anti-glomerular basement membrane disease as a potential complication of COVID-19: a case report and review of literature. Cureus 12:e12089
    [Google Scholar]
  67. 67.
    Sharma P, Uppal NN, Wanchoo R et al. 2020. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J. Am. Soc. Nephrol. 31:1948–58
    [Google Scholar]
  68. 68.
    Nopsopon T, Kittrakulrat J, Takkavatakarn K et al. 2021. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLOS Negl. Trop. Dis. 15:e0009156
    [Google Scholar]
  69. 69.
    Hsu CM, Weiner DE, Aweh G et al. 2021. COVID-19 infection among us dialysis patients: risk factors and outcomes from a national dialysis provider. Am. J. Kidney Dis. 77:748–56
    [Google Scholar]
  70. 70.
    Hsu CM, Weiner DE, Aweh G et al. 2021. COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider. Am. J. Kidney Dis. 77:748–56.e1
    [Google Scholar]
  71. 71.
    Anand S, Montez-Rath M, Han J et al. 2020. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet 396:1335–44
    [Google Scholar]
  72. 72.
    El Karoui K, De Vriese AS. 2022. COVID-19 in dialysis: clinical impact, immune response, prevention and treatment. Kidney Int. 101:883–94
    [Google Scholar]
  73. 73.
    Wu J, Li J, Zhu G et al. 2020. Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Clin. J. Am. Soc. Nephrol. 15:1139–45
    [Google Scholar]
  74. 74.
    Weinhandl ED, Wetmore JB, Peng Y et al. 2021. Initial effects of COVID-19 on patients with ESKD. J. Am. Soc. Nephrol. 32:1444–53
    [Google Scholar]
  75. 75.
    US Renal Data System 2020 USRDS annual data report: epidemiology of kidney disease in the United States Rep. Natl. Inst. Health, Natl. Inst. Diabetes Digest. Kidney Dis. Bethesda, MD:
  76. 76.
    Salerno S, Messana JM, Gremel GW et al. 2021. COVID-19 risk factors and mortality outcomes among Medicare patients receiving long-term dialysis. JAMA Netw. Open 4:e2135379
    [Google Scholar]
  77. 77.
    Kliger AS, Silberzweig J. 2020. Mitigating risk of COVID-19 in dialysis facilities. Clin. J. Am. Soc. Nephrol. 15:707–9
    [Google Scholar]
  78. 78.
    Chen JJ, Lee TH, Tian YC et al. 2021. Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw. Open 4:e2131749
    [Google Scholar]
  79. 79.
    Garcia P, Montez-Rath ME, Moore H et al. 2021. SARS-CoV-2 vaccine acceptability in patients on hemodialysis: a nationwide survey. J. Am. Soc. Nephrol. 32:1575–81
    [Google Scholar]
  80. 80.
    Akalin E, Azzi Y, Bartash R et al. 2020. Covid-19 and kidney transplantation. N. Engl. J. Med. 382:2475–77
    [Google Scholar]
  81. 81.
    Cravedi P, Mothi SS, Azzi Y et al. 2020. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am. J. Transplant. 20:3140–48
    [Google Scholar]
  82. 82.
    Pinchera B, Spirito L, Ferreri L et al. 2022. SARS-CoV-2 in kidney transplant patients: a real-life experience. Front. Med. 9:864865
    [Google Scholar]
  83. 83.
    Udomkarnjananun S, Kerr SJ, Townamchai N et al. 2021. Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. Sci. Rep. 11:20073
    [Google Scholar]
  84. 84.
    Hilbrands LB, Duivenvoorden R, Vart P et al. 2020. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA Collaboration. Nephrol. Dial. Transplant. 35:1973–83
    [Google Scholar]
  85. 85.
    Trujillo H, Caravaca-Fontan F, Sevillano A et al. 2020. SARS-CoV-2 infection in hospitalized patients with kidney disease. Kidney Int. Rep. 5:905–9
    [Google Scholar]
  86. 86.
    Azzi Y, Parides M, Alani O et al. 2020. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 98:1559–67
    [Google Scholar]
  87. 87.
    Cravedi P, Ahearn P, Wang L et al. 2021. Delayed kinetics of IgG, but not IgA, antispike antibodies in transplant recipients following SARS-CoV-2 infection. J. Am. Soc. Nephrol. 32:3221–30
    [Google Scholar]
  88. 88.
    Caillard S, Chavarot N, Bertrand D et al. 2021. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 100:477–79
    [Google Scholar]
  89. 89.
    Khairallah P, Aggarwal N, Awan AA et al. 2021. The impact of COVID-19 on kidney transplantation and the kidney transplant recipient—one year into the pandemic. Transpl. Int. 34:612–21
    [Google Scholar]
  90. 90.
    Ajaimy M, Liriano-Ward L, Graham JA, Akalin E. 2021. Risks and benefits of kidney transplantation during the COVID-19 pandemic: transplant or not transplant?. Kidney360 2:1179–87
    [Google Scholar]
  91. 91.
    Devresse A, De Greef J, Yombi JC et al. 2022. Immunosuppression and SARS-CoV-2 infection in kidney transplant recipients. Transplant. Direct 8:e1292
    [Google Scholar]
  92. 92.
    COVID-19 Treatment Guidelines Panel 2022. Coronavirus disease 2019 (COVID-19) treatment guidelines. Natl. Inst. Health https://www.covid19treatmentguidelines.nih.gov/. Accessed Apr. 30
  93. 93.
    Azzi Y, Bartash R, Scalea J et al. 2021. COVID-19 and solid organ transplantation: a review article. Transplantation 105:37–55
    [Google Scholar]
  94. 94.
    Major R, Selvaskandan H, Makkeyah YM et al. 2020. The exclusion of patients with CKD in prospectively registered interventional trials for COVID-19—a rapid review of international registry data. J. Am. Soc. Nephrol. 31:2250–52
    [Google Scholar]
  95. 95.
    Aiswarya D, Arumugam V, Dineshkumar T et al. 2021. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. Kidney Int. Rep. 6:586–93
    [Google Scholar]
  96. 96.
    Sorgel F, Malin JJ, Hagmann H et al. 2021. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. J. Antimicrob. Chemother. 76:825–27
    [Google Scholar]
/content/journals/10.1146/annurev-med-042420-104753
Loading
/content/journals/10.1146/annurev-med-042420-104753
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error